COX-2 contributes to P-glycoprotein-mediated multidrug resistance via phosphorylation of c-Jun at Ser63/73 in colorectal cancer

Carcinogenesis

Volumn 32, Issue 5, 2011, Pages 667-675

  Sui, Hua ^b   Zhou, Shoufeng ^b   Wang, Yan ^a   Liu, Xuan ^a   Zhou, Lihong ^a   Yin, Peihao ^a   Fan, Zhongze ^a   Li, Qi ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CYCLOOXYGENASE 2; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROTEIN C JUN; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; VINCRISTINE;

ARTICLE; CANCER CELL CULTURE; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 79955775908     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr016     Document Type: Article

References (45)

1. Kang, C.D. et al. (2000) Downregulation of JNK/SAPK activity is associated with the cross-resistance to P-glycoprotein-unrelated drugs in multidrug-resistant FM3A/M cells overexpressing P-glycoprotein. Exp. Cell Res., 256, 300-307.
2. Ling, V. (1997) Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother. Pharmacol., 40, S3-S8.
3. McKenna, S.L. et al. (1997) Multidrug resistance in leukaemia. Br. J. Haematol., 96, 659-674.
4. Butterfield, L. et al. (1997) c-Jun NH2-terminal kinase regulation of the apoptotic response of small cell lung cancer cells to ultraviolet radiation. J. Biol. Chem., 272, 10110-10116.
5. Chen, Y.R. et al. (1996) The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and gamma radiation. Duration of JNK activation may determine cell death and proliferation. J. Biol. Chem., 271, 31929-31936.
6. Zanke, B.W. et al. (1996) The stress-activated protein kinase pathway mediates cell death following injury induced by cis-platinum, UV irradiation or heat. Curr. Biol., 6, 606-613.
7. Guo, Y.L. et al. (1998) Correlation between sustained c-Jun N-terminal protein kinase activation and apoptosis induced by tumor necrosis factoralpha in rat mesangial cells. J. Biol. Chem., 273, 4027-4034.
8. Osborn, M.T. et al. (1996) Role of the stress-activated/c-Jun NH2-trminal kinase pathway in the cellular response to adriamycin and other chemotherapeutic drugs. J. Biol. Chem., 271, 30950-30955.
9. Fujita, T. et al. (2005) Proteasome inhibitors can alter the signaling pathways and attenuate the P-glycoproteinmediated multidrugresistance. Int. J. Cancer, 117, 670-682.
10. Miao, Z.H. et al. (2003) Transcription factor c-Jun activation represses mdr-1 gene expression. Cancer Res., 63, 4527-4532.
11. Patel, V.A. et al. (2002) Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase- J. Biol. Chem., 277, 38915-38920.
12. Nair, P. et al. (2003) Coprocytobiology: on the nature of cellular elements from stools in the pathophysiology of colonic disease. J. Clin. Gastroenterol., 36, S84-S93.
13. Saikawa, Y. et al. (2004) Cyclooxygenase-2 gene induction causes CDDP resistance in colon cancer cell line, HCT-15. Anticancer Res., 24, 2723-2728.
14. Sorokin, A. (2004) Cyclooxygenase-2: potential role in regulation of drug efflux and multidrug resistance phenotype. Curr. Pharm. Des., 10, 647-657.
15. Deng, W.L. et al. (2008) Reversal of multidrug resistance by "Changweiqing" on vincristine resistant human colorectal cancer cell line HCT8/V. Tumor, 28, 755-762.
16. Endicott, J.A. et al. (1989) The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem., 58, 137-171.
17. Ambudkar, S.V. et al. (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol., 39, 361-398.
18. Gottesman, M.M. et al. (2002) Multidrug resistance in cancer: role of ATPdependent transporters. Nat. Rev. Cancer, 2, 48-58.
19. Aller, S.G. et al. (2009) Structure of P-glycoprotein Reveals a molecular basis for poly-specific drug binding. Science, 323, 1718-1722.
20. Ratnasinghe, D. et al. (2001) Cyclooxygenase-2, P-glycoprotein-170 and drug resistance; is chemoprevention against multidrug resistance possible? Anticancer Res., 21, 2141-2147.
21. Awara, W.M. et al. (2004) The potential role of cyclooxygenase-2 inhibitors in the treatment of experimentally-induced mammary tumour: does celecoxib enhance the anti-tumour activity of doxorubicin? Pharm. Res., 50, 487-498.
22. Fantappie', O. et al. (2007) P-glycoprotein mediates celecoxib-induced apoptosis in multiple drug-resistant cell lines. Cancer Res., 67, 4915-4923.
23. Yu, L. et al. (2009) Enhancement of doxorubicin cytotoxicity on human esophageal squamous cell carcinoma cells by indomethacin and 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC236) via inhibiting P-glycoprotein activity. Mol. Pharmacol., 75, 1364-1373.
24. Xia, W. et al. (2009) Celecoxib enhanced the sensitivity of cancer cells to anticancer drugs by inhibition of the expression of P-glycoprotein through a COX-2-independent manner. J. Cell. Biochem., 108, 181-194.
25. van Vliet, E.A. et al. (2010) COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats. Neuropharmacology, 58, 404-412.
26. Roy, K.R. et al. (2010) Celecoxib inhibits MDR1 expression through COX-2-dependent mechanism in human hepatocellular carcinoma (HepG2) cell line. Cancer Chemother. Pharmacol., 65, 903-911.
27. Bassiouny, A.R. et al. (2010) Synergistic effect of celecoxib on 5-fluorouracil-induced apoptosis in hepatocellular carcinoma patients. Ann. Hepatol, 9, 410-418.
28. Lagadinou, E.D. et al. (2008) c-Jun N-terminal kinase activation failure is a new mechanism of anthracycline resistance in acute myeloid leukemia. Leukemia, 22, 1899-1908.
29. Zhang, Y. et al. (2009) JWA sensitizes P-glycoprotein-mediated drugresistant choriocarcinoma cells to etoposide via JNK and mitochondrialassociated signal pathway. J. Toxicol. Environ. Health A, 72, 774-781.
30. Bark, H. et al. (2010) PSC833, cyclosporine analogue, downregulatesMDR1 expression by activating JNK/c-Jun/AP-1 and suppressing NF-kappaB. Cancer Chemother. Pharmacol., 65, 1131-1136.
31. Weston, C.R. et al. (2002) The JNK signal transduction pathway. Curr. Opin. Genet. Dev., 12, 14-21.
32. Osborn, M.T. et al. (1996) Role of the stress-activated/c-Jun NH2-terminal protein kinase pathway in the cellular response to adriamycin and other chemotherapeutic drugs. J. Biol. Chem., 271, 30950-30655.
33. Comerford, K.M. et al. (2004) c-Jun NH2-terminal kinase activation contributes to hypoxia-inducible factor 1alpha-dependent P-glycoprotein expression in hypoxia. Cancer Res., 64, 9057-9061.
34. Teraishi, F. et al. (2005) JNK1-dependent antimitotic activity of thiazolidin compounds in human non-small-cell lung and colon cancer cells. Cell. Mol. Life Sci., 62, 2382-2389.
35. Takano, Y. et al. (2010) Up-regulation of connexin 32 gene by 5-aza-2'-deoxycytidine enhances vinblastine-induced cytotoxicity in human renal carcinoma cells via the activation of JNK signalling. Biochem. Pharmacol., 80, 463-470.
36. Xing, B. et al. (2007) Neuroprotection with pioglitazone against LPS insult on dopaminergic neurons may be associated with its inhibition of NF-kappaB and JNK activation and suppression of COX-2 activity. J. Neuroimmunol., 192, 89-98.
37. Ambudkar, S.V. et al. (2003) P-glycoprotein: from genomics to mechanism. Oncogene, 22, 7468-7485.
38. Hall, M.D. et al. (2009) Is resistance useless? multidrug resistance and collateral sensitivity. Trends Pharmacol. Sci., 30, 546-556.
39. Zhou, J. et al. (2006) Reversal of P-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-teriminal kinase. Cancer Res., 66, 445-452.
40. Zatelli, M.C. et al. (2007) Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression. Endocr. Relat. Cancer, 14, 1029-1038.
41. Kawasaki, K. et al. (2009) REIC/Dkk-3 overexpression downregulates Pglycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer. Cancer Gene Ther., 16, 65-72.
42. Newton, R. et al. (1997) Superinduction of COX-2 mRNA by cycloheximide and interleukin-1beta involves increased transcription and correlates with increased NF-kappaB and JNK activation. FEBS Lett., 418, 135-138.
43. Hunot, S. et al. (2004) JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc. Natl Acad. Sci. USA, 101, 665-670.
44. Ogunwobi, O. et al. (2006) Leptin stimulates proliferation and inhibits apoptosis in Barrett's esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation. Endocrinology, 147, 4505-4516.
45. Barrand, M.A. et al. (1997) Multidrug resistance-associated protein: a protein distinct from P-glycoprotein involved in cytotoxic drug expulsion. Gen. Pharmacol., 28, 639-645.